PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-168.99%
Negative EBIT growth while AVXL is at 7.04%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-230.56%
Negative operating income growth while AVXL is at 7.04%. Joel Greenblatt would press for urgent turnaround measures.
-176.90%
Negative net income growth while AVXL stands at 85.09%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
89.62%
EPS growth similar to AVXL's 86.00%. Walter Schloss would assume both have parallel share structures and profit trends.
89.62%
Similar diluted EPS growth to AVXL's 86.00%. Walter Schloss might see standard sector or cyclical influences on both firms.
2567.99%
Share count expansion well above AVXL's 6.65%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2567.99%
Diluted share count expanding well above AVXL's 6.65%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-298628.16%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-217028.56%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-67594.88%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-60146.79%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-86002.39%
Negative 3Y OCF/share CAGR while AVXL stands at 82.26%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-51844.29%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-93706.66%
Negative 5Y net income/share CAGR while AVXL is 62.36%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-45701.99%
Negative 3Y CAGR while AVXL is 76.72%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
3346.07%
Positive growth while AVXL is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
1899.20%
Positive 5Y equity/share CAGR while AVXL is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
720.41%
3Y equity/share CAGR above 1.5x AVXL's 49.02%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
104.51%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-98.43%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
92.16%
Debt shrinking faster vs. AVXL's 510.20%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
-30.73%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
522.30%
SG&A growth well above AVXL's 74.87%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.